Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
AssigneeIntervet Inc.
InventorsMohamad Morsey, Yuanzheng Zhang, Anasuya Saha
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions for treating canine atopic dermatitis that comprise a fusion protein that binds canine IL-22, a caninized anti-pruritic antibody, and a caninized anti-inflammatory antibody. The present invention further provides compositions that comprise a bispecific binding partners that comprises that fusion protein and a caninized anti-pruritic antibody or a caninized anti-inflammatory antibody, or alternatively, a bispecific antibody comprising a caninized anti-pruritic antibody and a caninized anti-inflammatory antibody, which in addition comprises a fusion protein that binds canine IL-22.
Claims19
A composition for treating atopic dermatitis in canines, wherein the composition comprises a bispecific binding partner comprising a heterodimer of (i) a fusion protein that binds canine IL-22 and (ii) a monomer of a caninized anti-pruritic antibody comprising a light chain and a heavy chain;
- wherein the fusion protein that binds canine IL-22 is selected from the group consisting of a canine IL-22RA1-Fc fusion protein and a canine IL-22RA2-Fc fusion protein,
- wherein the caninized anti-pruritic antibody is a caninized interleukin-31 (IL-31) antibody or a caninized interleukin-31 receptor alpha (IL-3IRA) antibody;
- wherein (a) the light chain of the caninized IL-31 antibody comprises a light chain variable region (VL) having an amino acid sequence of a VL of a light chain having the amino acid sequence of SEQ ID NO:11;
- and (b) the heavy chain of the caninized IL-31 antibody comprises a heavy chain variable region (VH) having an amino acid sequence of a VH of a heavy chain having the amino acid sequence of SEQ ID NO:15;
- or
- wherein (a) the light chain of the caninized IL-31 antibody comprises a VL having an amino acid sequence of a VL of a light chain having the amino acid sequence of SEQ ID NO:12;
- and (b) the heavy chain of the caninized IL-31 antibody comprises a VH having an amino acid sequence of a VH of a heavy chain having the amino acid sequence of SEQ ID NO:18;
- or
- wherein (a) the light chain of the caninized IL-3IRA antibody comprises a VL having an amino acid sequence of a VL of a light chain having the amino acid sequence of SEQ ID NO:52;
- and (b) the heavy chain of the caninized IL-3IRA antibody comprises a VH having an amino acid sequence of a VH of a heavy chain having the amino acid sequence of SEQ ID NO:53.
A composition for treating atopic dermatitis in canines comprising a bispecific antibody that comprises a monomer of a caninized anti-pruritic antibody comprising a heavy chain and a light chain and a monomer of a caninized anti-inflammatory antibody comprising a heavy chain and a light chain;
- wherein the caninized anti-pruritic antibody is a caninized interleukin-31 receptor alpha (IL-3IRA) antibody and the caninized anti-inflammatory antibody is a caninized interleukin-4 receptor alpha (IL-4R alpha) antibody;
- wherein (a) the light chain of the caninized IL-4R alpha antibody comprises a light chain variable region (VL) comprising a VL Complementarity-Determining Region 1 (CDR1), a VL CDR2, and a VL CDR3 and a heavy chain variable region (VH) comprising a VH CDR1, a VH CDR2, and a VH CDR3:
- wherein the VL CDR1 comprises the sequence of SEQ ID NO:
- 34, the VL CDR2 comprises the sequence of SEQ ID NO:36, the VL CDR3 comprises the sequence of SEQ ID NO:38, the VH CDR1 comprises the sequence of SEQ ID NO:28, the VH CDR2 comprises the sequence of SEQ ID NO:30, and the VH CDR3 comprises the sequence of SEQ ID NO:32;
- and
- wherein (a) the light chain of the caninized IL-3IRA antibody comprises a VL having an amino acid sequence of a VL of a light chain having the amino acid sequence of SEQ ID NO:52 and (b) the heavy chain of the caninized IL-31RA antibody comprises a VH having an amino acid sequence of a VH of a heavy chain having the amino acid sequence of SEQ ID NO:53.
Dependencies are inferred from the claim text.